3DPrint.com | Additive Manufacturing Business
·
Mon, 09 Mar 2026 12:00:07 +0000
Pete Pharma Deal with Atrium24 Signals Path for Broader 3D Printed Drug Commercialization
#3D printing
#additive manufacturing
• While I would guess we’re still probably at least several years away from 3D printed drugs being a commonplace reality, the growing number of companies with proprietary additive manufacturing (AM)...
Read original on 3DPrint.com | Additive Manufacturing Business
Related Stories
3DPrint.com | Additive Manufacturing Business
·
Fri, 03 Ap
Leading Chemical Manufacturer Kureha Makes Strategic Investment in Z-Polymers’ Advanced 3D Printing Materials
3DPrint.com | Additive Manufacturing Business
·
Fri, 03 Ap
Loughborough University Using Freemelt’s EBM Technology to Drive AM Research
3DPrint.com | Additive Manufacturing Business
·
Fri, 03 Ap
Canada Backs Aspect Biosystems With $280M to Scale Bioprinted Tissue Therapies
3DPrint.com | Additive Manufacturing Business
·
Fri, 03 Ap